

Special Issue

Cardiomyopathy and Precision Medicine: 2nd Edition

Message from the Guest Editor

The diagnosis of the most common forms of cardiomyopathies, have long been based on morphology and function by non-invasive diagnostic modalities. In addition, despite extensive studies on biophysical, cellular, and animal models, the current approaches to the management of patients with cardiomyopathies remain largely unchanged. Recent advances in genetics, proteomics, metabolomics, and microbiomics have broadened our understanding of the molecular and cellular pathophysiology of cardiovascular diseases including cardiomyopathies, which can potentially lead to more precise risk prediction and the discovery of optimal treatment strategies for individual patients. Novel approaches, such as artificial intelligence and machine learning to medical big data from various sources including clinical registries, electronic health records, biomarkers, medical images, and all spectrum of 'omics' data, have huge potential for empowering personalized medicine for cardiomyopathy patients. This Special Issue aims to the current knowledge and future perspectives in the potential analytic approaches leading to personalized medicine for cardiomyopathies.

Guest Editor

Dr. Yuji Nagatomo

Department of Cardiology, National Defense Medical College,
Tokorozawa, Saitama, Japan

Deadline for manuscript submissions

25 December 2024



Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/si/188703

*Journal of Personalized
Medicine*
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/journal/

[jpm](https://jpm.mdpi.com)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).